Biogen to Centralize Operations in Kendall Common's First Building at MIT Location
Biotech titan Biogen, a trailblazer in the Cambridge, Massachusetts-based Kendall Square innovation district, announced plans to centralize its operations in a new facility at MIT's Kendall Common development starting in 2028.
The move highlights the company's enduring commitment to Cambridge and its burgeoning biomedical ecosystem. MIT President Sally Kornbluth praised the decision, referring to Kendall Square's "talent in proximity" motto and expressing optimism for the regional innovation landscape.
Spanning approximately 580,000 square feet, the new facility will house Biogen's research and development teams alongside its global and North American commercialization organizations. The building will incorporate advanced conservation, efficiency, and sustainable design elements.
The project, a joint venture between MIT Investment Management Company and BioMed Realty—a Blackstone Real Estate portfolio company—will activate the 75 Broadway corner, preserving the nearby 6th Street Walkway. Anantha Chandrakasan, MIT's chief innovation and strategy officer, highlighted the fruitful partnership between Biogen and MIT, noting the company's role in shaping the local life sciences sector.
The 10-acre Kendall Common development aims to include residences, offices, labs, retail spaces, and community facilities. The project recently underwent a 10-year review process and federal agreement, culminating in the opening of the MIT-built John A. Volpe National Transportation Systems Center.
Biogen's nearly five-decade presence has been instrumental in transforming Kendall Square into a global hub for biotech innovation. Historically an industrial area, the district has undergone significant redevelopment, with influential projects such as the Cambridge Centre and Akamai Building playing key roles in reshaping the neighborhood. The Kendall Hotel, originally the Engine 7 Firehouse built in 1894, exemplifies the blend of historic infrastructure and modern uses that defines Kendall Square.
Biogen's commitment to its ongoing presence in Kendall Common suggests the company remains a cornerstone tenant and partner in future development projects. While specific future plans were not detailed,Biogen's longstanding involvement in the area signals an intention to sustain and expand its influence in Kendall Square's evolving landscape.
- Biogen's decision to centralize operations in MIT's Kendall Common development indicates the company's continued dedication to science in the Cambridge, Massachusetts ecosystem.
- The new facility, encompassing 580,000 square feet, will encapsulate Biogen's research and development teams, as well as its global and North American commercialization organizations, in the realm of technology.
- The project, initiated by MIT Investment Management Company and BioMed Realty, will incorporate green design elements, reflecting the company's commitment to sustainable transportation and medicine.
- The 10-acre Kendall Common development, including residences, offices, labs, retail spaces, and community facilities, will foster innovation and society's advancement in the areas of real-estate, finance, and investing.
- The Kendall Common development, as part of the burgeoning biomedical ecosystem, will provide an opportunity for news outlets to report on groundbreaking stories in biology, genetics, and other related fields.
- The district's transformation from an industrial area to a global hub for biotech innovation, propelled by companies like Biogen, has been driven by society's relentless pursuit of innovation.
- The blending of historic infrastructure like the Kendall Hotel with modern uses in Kendall Square exemplifies the intertwining of past, present, and future in the commercialization and development of society.
- Biogen's ongoing presence in Kendall Square not only solidifies its role as a key player in the area's life sciences sector but also suggests its future intentions to contribute to the district's ongoing evolution and growth.
